Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous immunoglobulins (Hyqvia) with rHuPH20 in multifocal motor neuropathy
2015-000828-28Phase 3Active
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Human normal immunoglobulin G in multifocal motor neuropathy (MMN) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Primary safety and tolerability endpoint and Primary efficacy non-inferiority endpoint. Started Nov 2015; status: active.
02
Drugs
Human normal immunoglobulin G
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2015-000828-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000828-28.